Clinical trials · Houston, TX
Refractory Cancer clinical trials in Houston
We’re tracking 65 recruiting refractory cancer studies with a site in or near Houston — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Houston
- NCT07133425RecruitingPhase 2
Study of a new immune drug for resistant lung cancer
This trial tests a new drug (SAR445877) for people with advanced non-small cell lung cancer whose cancer continued to grow despite immunotherapy. It aims to see if this treatment can help when other options have stopped working.
Houston, TexasAges 18 years+ - NCT05828069RecruitingPhase 2
Tovorafenib for young people with worsening Langerhans cell histiocytosis
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Houston, TexasAges 6 months–22 years - NCT03911388RecruitingPhase 1
HSV G207 for Children with Recurrent Cerebellar Brain Tumors
This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.
Houston, TexasAges 3–22 - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Houston, TexasAges 18 years+ - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT07032727RecruitingPhase 2
Olutasidenib plus targeted therapy for relapsed IDH1-mutated myeloid cancers
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
Houston, TexasAges 18 years+ - NCT07306559RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
Houston, TexasAges 18 years+ - NCT05010122RecruitingPhase 1/Phase 2
Testing venetoclax and gilteritinib with ASTX727 for FLT3 leukemia
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
Houston, TexasAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Houston, TexasAges 18 years+ - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Houston, TexasAges 12 years+ - NCT07311746RecruitingPhase 1/Phase 2
Study of cladribine, ruxolitinib, and venetoclax for T-PLL
This trial tests a combination of three drugs (cladribine, ruxolitinib, and venetoclax) for people with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to prior treatment. The goal is to see if this therapy can help control the disease.
Houston, TexasAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Houston, TexasAges 18 years+ - NCT04169737RecruitingPhase 2
Acalabrutinib and venetoclax for high-risk CLL or SLL
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
Houston, TexasAges 18 years+ - NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Houston, TexasAges 12 years+ - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Houston, TexasAges 18 years+ - NCT03683433RecruitingPhase 2
Enasidenib plus azacitidine for IDH2-mutated AML
This trial studies the combination of enasidenib and azacitidine in people with acute myeloid leukemia (AML) that has an IDH2 gene mutation. It may help control the leukemia when prior treatments didn’t work or the disease came back.
Houston, TexasAges 18 years+ - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
Houston, TexasAges 18 years+ - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Houston, TexasAges 12 years+ - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Houston, TexasAges 18 years+
Hear when a new Refractory Cancer trial opens near Houston, TX
We’ll email you when one opens near Houston, TX — at most once a week, no account needed, unsubscribe anytime.
Refractory Cancer trials in other cities
Where these studies are running near Houston
Institutions with a site for the recruiting refractory cancer studies listed above.
- The University of Texas MD Anderson Cancer Center · 23 studies
- Baylor College of Medicine · 2 studies
- NEXT Oncology
- University of Texas Medical Branch
What taking part in a refractory cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory cancer studies in Texas.
Common questions
- Are there refractory cancer clinical trials near Houston?
- Yes. We're currently tracking 65 recruiting refractory cancer studies with a site near Houston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory cancer study near Houston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Houston to take part?
- Not necessarily. These studies have a site near Houston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory cancer studies open near Houston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.